NR4A1 and triple-negative breast carcinoma: A handful of reports have suggested that irinotecan showed potentially promising results in triple negative breast cancer (3, 9), but unlike those studies, we found HR positive or non-triple negative patients had longer PFS treated with irinotecan compared with hormone receptor-negative patients.